Novel murine mammary epithelial cell lines that form osteolytic bone metastases: Effect of strain background on tumor homing

Clinical and Experimental Metastasis

Volumn 20, Issue 2, 2003, Pages 111-120

  Chen, Yanping ^a   Rittling, Susan R ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Bone metastasis; Breast cancer; Genetic modifiers; Metastatic pattern; Polyoma middle T

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; MEDROXYPROGESTERONE ACETATE; OSTEOPONTIN; VIRUS MIDDLE T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CARCINOGENESIS; CELL LINE; CONTROLLED STUDY; CORTICAL BONE; DNA MODIFICATION; GENE ACTIVATION; GENE DISRUPTION; HEREDITY; HOST; KNOCKOUT MOUSE; LIVER METASTASIS; LUNG METASTASIS; MALIGNANT TRANSFORMATION; METASTASIS; METASTASIS PATTERN; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE RAS; OSTEOLYSIS; POLYOMA VIRUS; PROTEIN EXPRESSION; SOFT TISSUE METASTASIS; STRAIN DIFFERENCE; TRABECULAR BONE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; GENES, RAS; HEART VENTRICLES; HUMANS; KERATINS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MEDROXYPROGESTERONE 17-ACETATE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; NEOPLASM CIRCULATING CELLS; OSTEOLYSIS; OSTEOPONTIN; RETROVIRIDAE; SIALOGLYCOPROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037251307     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022675031185     Document Type: Article

References (54)

1. Tas F, Yavuz E, Aydiner A et al. Angiogenesis and p53 protein expression in breast cancer: Prognostic roles and interrelationships. Am J Clin Oncol 2000; 23(6): 546-53.
2. Mundy G. Preclinical models of bone metastases. Semin Oncol 2001; 28(4 Suppl 11): 2-8.
3. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80(8 Suppl): 1588-94.
4. Yin JJ, Selander K, Chirgwin JM et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103(2): 197-206.
5. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain 1997; 69(1-2): 1-18.
6. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999; 6(3): 333-47.
7. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000; 88(12 Suppl): 2892-8.
8. Guise TA, Yin JJ, Taylor SD et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98(7): 1544-9.
9. Yoneda T, Williams PJ, Hiraga T et al. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16(8): 1486-95.
10. Kakonen SM, Selander KS, Chirgwin JM et al. TGFbeta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002; 277(27): 24571-8.
11. Wu YM, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 2000; 83: 156-63.
12. Nemoto H, Rittling SR, Yoshitake H et al. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 2001; 16(4): 652-9.
13. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997; 17(1): 1-15.
14. Yoshitake H, Rittling SR, Denhardt DT et al. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 1999; 96(14): 8156-60 [published erratum appears in Proc Natl Acad Sci USA 1999 Sep 14; 96(19): 10944].
15. Ishijima M, Rittling SR, Yamashita T et al. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 2001; 193(3): 399-404.
16. Chellaiah M, Fitzgerald C, Alvarez JI et al. c-Src is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase. J Biol Chem 1998; 273(19): 11908-16.
17. Suzuki K, Zhu B, Rittling SR et al. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 2002; 17(8): 1486-97.
18. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment. Semin Oncol 2001; 28(2 Suppl 6): 35-44.
19. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48(23): 6876-81.
20. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994; 32(1): 73-84.
21. Takayanagi H, Ogasawara K, Hida S et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408(6812): 600-5.
22. Wang R, Zhang L, Zhang X et al. Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells. Eur J Immunol 2002; 32(4): 1090-8.
23. Lelekakis M, Moseley JM, Martin TJ et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999; 17(2): 163-70.
24. Yoneda T, Michigami T, Yi B et al. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 1999; 25(5): 293-9.
25. Smith GS, Walford RL, Mickey MR. Lifespan and incidence of cancer and other diseases in selected long-lived inbred mice and their F 1 hybrids. J Natl Cancer Inst 1973; 50(5): 1195-213.
26. Rittling SR, Matsumoto HN, McKee MD et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 1998; 13(7): 1101-11.
27. Soriano P, Montgomery C, Geske R et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64(4): 693-702.
28. Dahl J, Thathamangalam U, Freund R et al. Functional asymmetry of the regions juxtaposed to the membrane-binding sequence of polyomavirus middle T antigen. Mol Cell Biol 1992; 12(11): 5050-8.
29. Morgenstern JP, Land H. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18(12): 3587-96.
30. Guo X, Zhang YP, Mitchell DA et al. Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol 1995; 15: 476-87.
31. Rittling SR, Novick KW. Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ 1997; 8: 1061-9.
32. Rittling SR, Feng F. Detection of mouse osteopontin by western blotting. Biochem Biophys Res Comm 1998; 250: 287-92.
33. Aldaz CM, Liao QY, LaBate M et al. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 1996; 17(9): 2069-72.
34. Feng F, Rittling SR. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res Treat 2000; 63(1): 71-9.
35. Guy CT, Cardiff RD, Muller WJ. Activated neu induces rapid tumor progression. J Biol Chem 1996; 271 (13): 7673-8.
36. Maglione JE, Moghanaki D, Young LJ et al. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001; 61(22): 8298-305.
37. Yoneda T, Sasaki A, Dunstan C et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99(10): 2509-17.
38. Hunter KW, Broman KW, Voyer TL et al. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms 1. Cancer Res 2001; 61(24): 8866-72.
39. Le Voyer T, Rouse J, Lu Z et al. Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density. Genomics 2001; 74(3): 253-61.
40. Le Voyer T, Lu Z, Babb J et al. An epistatic interaction controls the latency of a transgene-induced mammary tumor. Mamm Genome 2000; 11(10): 883-9.
41. Seraj MJ, Samant RS, Verderame MF et al. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMSI, encoded at chromosome 11q13. Cancer Res 2000; 60(11): 2764-9.
42. Dietrich WF, Lander ES, Smith JS et al. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 1993; 75(4): 631-9.
43. MacPhee M, Chepenik KP, Liddell RA et al. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995; 81 (6): 957-66.
44. Silverman KA, Koratkar R, Siracusa LD et al. Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. Genome Res 2002; 12(1): 88-97.
45. Felding-Habermann B, O'Toole TE, Smith JW et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001; 98(4): 1853-8.
46. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410(6824): 50-6.
47. Taichman RS, Cooper C, Keller ET et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62(6): 1832-7.
48. Scotton CJ, Wilson JL, Milliken D et al. Epithelial cancer cell migration: A role for chemokine receptors? Cancer Res 2001; 61(13): 4961-5.
49. Chambers AF, Naumov GN, Varghese HJ et al. Critical steps in hematogenous metastasis: An overview. Surg Oncol Clin N Am 2001; 10(2): 243-55, vii.
50. Varghese HJ, Davidson MT, MacDonald IC et al. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res 2002; 62(3): 887-91.
51. Beamer WG, Donahue LR, Rosen CJ et al. Genetic variability in adult bone density among inbred strains of mice. Bone 1996; 18(5): 397-403.
52. Serrano M, Lin AW, McCurrach ME et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and pl6INK4a. Cell 1997; 88(5): 593-602.
53. Ichaso N, Dilworth SM. Cell transformation by the middle T-antigen of polyoma virus. Oncogene 2001; 20(54): 7908-16.
54. Nicolson GL, Moustafa AS. Metastasis-Associated genes and metastatic tumor progression. In Vivo 1998; 12(6): 579-88.